Personal Investment Vitae

Home > Personal Investment Vitae

AYA Personal Investment Vitae as of January 2026
Charlene Vos @Charlene Vos
Platinum member since January 2017

Location: United States

Gender: Female

Asset investment style: Quantitative fundamental analysis

Market capitalization:

$8,158,234talents

Virtual portfolio value:

$5,264,374talents

Net overall return per annum:

20.09%

AYA current rank order:

#6

Asset investment philosophy:
Charlene Vos trades U.S. stocks with the top #26 to #500 positive alpha signals.

Top 10 profitable stock transactions since January 2020Strategy

Symbol Company Buy Sell Share Volume Return (%) Profit ($)
RMBL RumbleOn Inc. Class B Common Stock $0.36 $7.95 32,466 +2,108.33% $246,417
BQ Boqii Holding Limited American Depositary Shares representing Class A Ordinary Shares $0.36 $3.36 41,969 +833.33% $125,907
BQ Boqii Holding Limited Class A Ordinary Shares $0.36 $3.36 41,969 +833.33% $125,907
UMAC Unusual Machines Inc. Common Stock $1.87 $18.73 7,344 +901.60% $123,820
SXTP 60 Degrees Pharmaceuticals Inc. Common Stock $0.15 $1.34 88,993 +793.33% $105,902
XBIOW Xenetic Biosciences Inc. Warrants $2.00 $23.16 4,611 +1,058.00% $97,569
VATE INNOVATE Corp. Common Stock $0.53 $4.14 25,186 +681.13% $90,921
SSNT SilverSun Technologies Inc. Common Stock $18.59 $130.48 696 +601.88% $77,875
LGVN Longeveron Inc. Class A Common Stock $3.45 $26.25 2,167 +660.87% $49,408
LSCC Lattice Semiconductor Corporation Common Stock $6.97 $48.04 1,161 +589.24% $47,682
Sum $1,091,408

Top 20 influencers

#1 - #5 #6 - #10 #11 - #15 #15 - #20
@Andy Yeh Alpha

Blog+More

Chinese trade delegation offers to boost purchases of U.S. agricultural products to reach an interim trade deal with the Trump administration.

Peter Prince

2019-11-03 12:30:00 Sunday ET

Chinese trade delegation offers to boost purchases of U.S. agricultural products to reach an interim trade deal with the Trump administration.

Chinese trade delegation offers to boost purchases of U.S. agricultural products to reach an interim trade deal with the Trump administration. Chinese Vice

+See More

The unique controversial management style of Steve Jobs helps translate his business acumen into smart product development.

Dan Rochefort

2020-03-26 10:31:00 Thursday ET

The unique controversial management style of Steve Jobs helps translate his business acumen into smart product development.

The unique controversial management style of Steve Jobs helps translate his business acumen into smart product development. Jay Elliot (2012) Leading

+See More

HPE CEO Meg Whitman decides to step down after her 6-year stint at the technology giant.

Charlene Vos

2017-11-07 09:38:00 Tuesday ET

HPE CEO Meg Whitman decides to step down after her 6-year stint at the technology giant.

HPE CEO Meg Whitman has run both eBay and Hewlett Packard within Fortune 500 and now has decided to step down after her 6-year stint at the technology giant

+See More

Successful founders focus on their continuous growth, passion, perseverance, and the collective wisdom of most team members.

Laura Hermes

2020-06-17 09:23:00 Wednesday ET

Successful founders focus on their continuous growth, passion, perseverance, and the collective wisdom of most team members.

Successful founders focus on their continuous growth, passion, perseverance, and the collective wisdom of most team members. William Ferguson (2013) &

+See More

CNBC news anchor Becky Quick interviews Warren Buffett in early-2019.

James Campbell

2019-04-07 13:39:00 Sunday ET

CNBC news anchor Becky Quick interviews Warren Buffett in early-2019.

CNBC news anchor Becky Quick interviews Warren Buffett in early-2019. Buffett explains the fact that book value fluctuations are a metric that has lost rele

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More